Company / Current Liabilities per Share
Matinas BioPharma Holdings, Inc. Current Liabilities per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities per Share
$0.61
FY2024
5-year range
$0.01 / $0.61
FY2020-FY2024
Trend
+4983.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities per Share changed +4984% YoY in FY2024, a notable deviation from the 9-year average annual change of +545%.
Based on SEC 10-K filings.
0.61 in FY2024 with a 5-year CAGR of +86.3%.
Increased from $0.02 to $0.61 over the past 2 years.
Current Liabilities per Share over time
Growth rates
- 3-Year CAGR
- +204.5%
- 5-Year CAGR
- +86.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, current liabilities per share increased 4983.9% year-over-year.
- Lowest current liabilities per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Liabilities per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.61 | +4983.9% |
| FY2023 | $0.01 | -39.1% |
| FY2022 | $0.02 | -8.8% |
| FY2021 | $0.02 | -0.6% |
| FY2020 | $0.02 | -20.0% |
| FY2019 | $0.03 | -10.1% |
| FY2018 | $0.03 | -20.5% |
| FY2017 | $0.04 | +51.4% |
| FY2016 | $0.03 | -27.7% |
| FY2015 | $0.03 | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026